

# Ashley Cimino-Mathews

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2700524/publications.pdf>

Version: 2024-02-01

96  
papers

4,307  
citations

101543

36  
h-index

118850

62  
g-index

96  
all docs

96  
docs citations

96  
times ranked

7590  
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer. <i>Surgical Pathology Clinics</i> , 2022, 15, 105-120.	1.7	6
2	Developing Asymmetries without Sonographic Correlate at Digital Breast Tomosynthesis. <i>Radiology</i> , 2022, 302, 525-532.	7.3	3
3	Weight Gain after Hormone Receptor-Positive Breast Cancer. <i>Current Oncology</i> , 2022, 29, 4090-4103.	2.2	3
4	Quiescent cancer cells: Therapeutic targets to overcome immunotherapy resistance?. <i>Med</i> , 2022, 3, 358-360.	4.4	0
5	Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls. <i>Modern Pathology</i> , 2021, 34, 62-77.	5.5	42
6	Endosalpingiosis Is Negative for GATA3. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1448-1452.	2.5	2
7	HER-2 Amplification in Uterine Serous Carcinoma and Serous Endometrial Intraepithelial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 708-715.	3.7	13
8	Continuing Undergraduate Pathology Medical Education in the Coronavirus Disease 2019 (COVID-19) Global Pandemic: The Johns Hopkins Virtual Surgical Pathology Clinical Elective. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 814-820.	2.5	15
9	Tumor-infiltrating lymphocytes and PD-L1 in breast cancer (and, what happened to medullary) <a href="#">Tj ETQq1 1 0.784314 rgBT /Overlock 10</a>	0.4	1
10	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). <i>Clinical Cancer Research</i> , 2021, 27, 5828-5837.	7.0	18
11	Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2247-2256.	1.6	22
12	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
13	Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5688-5696.	7.0	12
14	Tomosynthesis-Guided Vacuum-Assisted Breast Biopsy of Architectural Distortion Without a Sonographic Correlate: A Retrospective Review. <i>American Journal of Roentgenology</i> , 2021, 217, 845-854.	2.2	18
15	Radiologic and Pathologic Correlation of Invasive Lobular Carcinoma of the Breast. <i>Current Breast Cancer Reports</i> , 2021, 13, 319-330.	1.0	1
16	High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 25-35.	2.5	14
17	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 545-551.	7.0	100
18	Artifactual Displacement of Ductal Carcinoma In Situ (ADDCIS) (Toothpaste Effect). <i>American Journal of Surgical Pathology</i> , 2020, 44, 120-128.	3.7	2

#	ARTICLE	IF	CITATIONS
19	Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. <i>Gynecologic Oncology</i> , 2020, 159, 17-22.	1.4	42
20	Clinical outcomes of prexasertib monotherapy in recurrent <i>BRCA</i> wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses. , 2020, 8, e000516.		12
21	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.	7.0	126
22	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
23	Tumour-infiltrating lymphocytes (TILs) and <i>BRCA</i> -like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. <i>European Journal of Cancer</i> , 2020, 127, 240-250.	2.8	21
24	Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors. <i>Nature Communications</i> , 2020, 11, 1723.	12.8	64
25	A clinical study of tremelimumab alone or in combination with olaparib in patients with advanced epithelial ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6045-6045.	1.6	4
26	Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6084-6084.	1.6	1
27	Accuracy and clinical implications of pre-operative breast core needle biopsy diagnoses of fibroepithelial neoplasms and sarcomatoid carcinomas. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 51-56.	2.5	4
28	DNA Methylation Markers for Breast Cancer Detection in the Developing World. <i>Clinical Cancer Research</i> , 2019, 25, 6357-6367.	7.0	21
29	TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 714-722.	1.6	36
30	MON-419 Sellar Plasmacytoma: A Commonly Misdiagnosed Sellar Mass. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
31	Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. <i>Human Pathology</i> , 2018, 74, 135-147.	2.0	39
32	A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 425-430.	2.5	0
33	Axillary Lymph Node Inclusions. <i>Surgical Pathology Clinics</i> , 2018, 11, 43-59.	1.7	11
34	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	5.5	278
35	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i> -like status, tumor-infiltrating immune cells and survival. <i>Oncolmmunology</i> , 2018, 7, e1509820.	4.6	80
36	Metastatic breast cancer simulating well-differentiated neuroendocrine neoplasms of visceral organs. <i>Human Pathology</i> , 2018, 82, 76-86.	2.0	6

#	ARTICLE	IF	CITATIONS
37	TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.. Journal of Clinical Oncology, 2018, 36, 511-511.	1.6	4
38	Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component. Clinical Cancer Research, 2017, 23, 4875-4884.	7.0	35
39	MYB Labeling by Immunohistochemistry Is More Sensitive and Specific for Breast Adenoid Cystic Carcinoma than MYB Labeling by FISH. American Journal of Surgical Pathology, 2017, 41, 973-979.	3.7	52
40	Peripheral nerve sheath tumors of the breast. Seminars in Diagnostic Pathology, 2017, 34, 420-426.	1.5	13
41	Fine-needle aspiration of metastatic melanoma presenting as bilateral breast cysts. Diagnostic Cytopathology, 2017, 45, 446-451.	1.0	1
42	Utility of Sox10 labeling in metastatic breast carcinomas. Human Pathology, 2017, 67, 205-210.	2.0	42
43	PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. Modern Pathology, 2017, 30, 1551-1560.	5.5	35
44	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 379-386.	7.0	50
45	Squamous cell carcinoma complicating a chronic lesion of hidradenitis suppurativa: a case report and review of the literature. International Wound Journal, 2017, 14, 435-438.	2.9	53
46	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. Journal of Clinical Oncology, 2017, 35, 2193-2202.	1.6	209
47	Mutational profiles of breast cancer metastases from a rapid autopsy series reveal multiple evolutionary trajectories. JCI Insight, 2017, 2, .	5.0	19
48	A subset of fat-predominant angiomyolipomas label for MDM2 : a potential diagnostic pitfall. Human Pathology, 2016, 57, 7-12.	2.0	15
49	Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens. American Journal of Surgical Pathology, 2016, 40, 1090-1099.	3.7	7
50	Adjuvant radiation use in older women with early-stage breast cancer at Johns Hopkins. Breast Cancer Research and Treatment, 2016, 160, 291-296.	2.5	17
51	Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2016, 34, 4390-4397.	1.6	51
52	Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system. Ca-A Cancer Journal for Clinicians, 2016, 66, 408-436.	329.8	33
53	The immune microenvironment of breast ductal carcinoma in situ. Modern Pathology, 2016, 29, 249-258.	5.5	119
54	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Human Pathology, 2016, 47, 52-63.	2.0	284

#	ARTICLE	IF	CITATIONS
55	A Clinicopathologic Analysis of 45 Patients With Metaplastic Breast Carcinoma. American Journal of Clinical Pathology, 2016, 145, 365-372.	0.7	72
56	Benign and low-grade fibroepithelial neoplasms of the breast have low recurrence rate after positive surgical margins. Modern Pathology, 2016, 29, 259-265.	5.5	52
57	The role of GATA3 in breast carcinomas: a review. Human Pathology, 2016, 48, 37-47.	2.0	101
58	Metastatic Disease to the Breast From Extramammary Malignancies: A Multimodality Pictorial Review. Current Problems in Diagnostic Radiology, 2016, 45, 225-232.	1.4	44
59	Metastases to the Breast. , 2016, , 819-851.		1
60	Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget, 2016, 7, 6281-6293.	1.8	76
61	Reflex Estrogen Receptor/Progesterone Receptor/Human Epidermal Growth Factor Receptor 2 (ER/PR/Her2) Analysis of Breast Cancers in Needle Core Biopsy Specimens Dramatically Increases Health Care Costs. American Journal of Surgical Pathology, 2015, 39, 939-947.	3.7	9
62	Metastatic metaplastic breast carcinoma mimicking pulmonary squamous cell carcinoma on fine-needle aspiration. Diagnostic Cytopathology, 2015, 43, 844-849.	1.0	6
63	Synchronous bilateral breast carcinomas with divergent radiographic presentations: Radiologic-pathologic correlation of invasive mucinous and ductal carcinomas. Human Pathology: Case Reports, 2015, 2, 63-66.	0.2	0
64	Telomere length alterations unique to invasive lobular carcinoma. Human Pathology, 2015, 46, 1197-1203.	2.0	7
65	<i>HER2</i> missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6205-14.	7.1	69
66	Practice pattern treating older women with early stage breast cancer at Johns Hopkins.. Journal of Clinical Oncology, 2015, 33, 9529-9529.	1.6	0
67	Immune targeting in breast cancer. Oncology, 2015, 29, 375-85.	0.5	72
68	NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas. Journal of Clinical Pathology, 2014, 67, 768-771.	2.0	27
69	Frozen section evaluation of breast carcinoma sentinel lymph nodes: a retrospective review of 1,940 cases. Breast Cancer Research and Treatment, 2014, 148, 355-361.	2.5	34
70	<i>MACROD2</i> overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17606-17611.	7.1	56
71	A Subset of Nondescript Axillary Lymph Node Inclusions Have the Immunophenotype of Endosalpingiosis. American Journal of Surgical Pathology, 2014, 38, 1612-1617.	3.7	18
72	A Subset of Malignant Phyllodes Tumors Express p63 and p40. American Journal of Surgical Pathology, 2014, 38, 1689-1696.	3.7	77

#	ARTICLE	IF	CITATIONS
73	Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2643-2650.	7.0	341
74	Cytologic and histologic findings of iron pill-induced injury of the lower respiratory tract. <i>Diagnostic Cytopathology</i> , 2013, 41, 901-903.	1.0	13
75	GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. <i>Human Pathology</i> , 2013, 44, 1341-1349.	2.0	192
76	Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. <i>Human Pathology</i> , 2013, 44, 959-965.	2.0	138
77	EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 741-752.	2.5	44
78	Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. <i>Human Pathology</i> , 2013, 44, 2055-2063.	2.0	95
79	A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway. <i>Human Pathology</i> , 2013, 44, 2494-2500.	2.0	27
80	Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model. <i>Vaccine</i> , 2013, 31, 2449-2456.	3.8	13
81	GATA-3 Immunohistochemistry in the Differential Diagnosis of Adenocarcinoma of the Urinary Bladder. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1756-1760.	3.7	58
82	HOXB13 Mediates Tamoxifen Resistance and Invasiveness in Human Breast Cancer by Suppressing ER $\alpha$ and Inducing IL-6 Expression. <i>Cancer Research</i> , 2013, 73, 5449-5458.	0.9	80
83	Borderline Atypical Ductal Hyperplasia/Low-grade Ductal Carcinoma In Situ on Breast Needle Core Biopsy Should Be Managed Conservatively. <i>American Journal of Surgical Pathology</i> , 2013, 37, 913-923.	3.7	27
84	Digoxin as an inhibitor of global hypoxia inducible factor-1 $\alpha$ (HIF1 $\alpha$ ) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS1144-TPS1144.	1.6	2
85	MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. <i>Modern Pathology</i> , 2012, 25, 378-387.	5.5	67
86	Detection of Human Papillomavirus in Small Cell Carcinomas of the Anus and Rectum. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1087-1092.	3.7	26
87	Complete Radiologic Response and Long-Term Survival With Use of Systemic High-Dose Methotrexate for Breast Cancer-associated Leptomeningeal Disease. <i>Clinical Breast Cancer</i> , 2012, 12, 445-449.	2.4	6
88	Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. <i>Human Pathology</i> , 2012, 43, 1003-1011.	2.0	49
89	Small Cell Carcinoma ex-Pleomorphic Adenoma of the Parotid Gland. <i>Head and Neck Pathology</i> , 2012, 6, 502-506.	2.6	15
90	Pleomorphic hyalinizing angiectatic tumor: Cytomorphologic features on fine-needle aspiration. <i>Diagnostic Cytopathology</i> , 2011, 39, 214-217.	1.0	7

#	ARTICLE	IF	CITATIONS
91	Diagnostic Use of PAX8, CAIX, TTF-1, and TGB in Metastatic Renal Cell Carcinoma of the Thyroid. American Journal of Surgical Pathology, 2011, 35, 757-761.	3.7	48
92	Carcinoma ex Pleomorphic Adenoma of the Nasal Cavity. Head and Neck Pathology, 2011, 5, 405-409.	2.6	37
93	Metastatic urothelial carcinoma with signet ring features: Cytomorphologic findings in abdominal paracentesis. Diagnostic Cytopathology, 2011, 39, 132-134.	1.0	11
94	Atypical granular cell tumor of the thyroid: Cytomorphologic features on fine needle aspiration. Diagnostic Cytopathology, 2011, 39, 608-611.	1.0	20
95	The Clinicopathologic Correlates of Cellular Atypia in Urinary Cytology of Ileal Neobladders. Acta Cytologica, 2011, 55, 449-454.	1.3	14
96	Iron Pill-induced Tumefactive Mucosal Injury of the Hypopharynx. American Journal of Surgical Pathology, 2010, 34, 1720-1722.	3.7	13